BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed LLY catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:8f760bdc5e5c6bd7c516@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:LLY P2 readout (est.): A Study to Evaluate LY3537021 for the Treatm
 ent of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
DESCRIPTION:A Study to Evaluate LY3537021 for the Treatment of Nausea and V
 omiting Caused by Chemotherapy in Adults With Cancer\nNCT07169851 | PHASE2
  | RECRUITING | sponsor: Eli Lilly and Company\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nDate precision: month 
 (shown on the first day)\nTicker LLY (confidence 0.95)\nSource: https://cl
 inicaltrials.gov/study/NCT07169851\nScheduling/reference data from public 
 records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07169851
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:95cb84f41bbc7ad69459@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:LLY P2 readout (est.): A Study Comparing Abemaciclib Plus Temozolom
 ide to Temozolomide Monotherapy in Children and Young Adults With High-gra
 de Glioma Following Radiotherapy
DESCRIPTION:A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide
  Monotherapy in Children and Young Adults With High-grade Glioma Following
  Radiotherapy\nNCT06413706 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Eli
  Lilly and Company\nPrimary completion date (ESTIMATED)\; top-line results
  usually follow later.\nDate precision: month (shown on the first day)\nTi
 cker LLY (confidence 0.95)\nSource: https://clinicaltrials.gov/study/NCT06
 413706\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06413706
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:722c7e791d64f34151bb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:LLY P3 readout (est.): ADVANCE
DESCRIPTION:A Platform Trial for Pediatric Participants With Obesity or Ove
 rweight (LY900040)\nNCT06672549 | PHASE3 | RECRUITING | sponsor: Eli Lilly
  and Company\nPrimary completion date (ESTIMATED)\; top-line results usual
 ly follow later.\nDate precision: month (shown on the first day)\nTicker L
 LY (confidence 0.95)\nSource: https://clinicaltrials.gov/study/NCT06672549
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06672549
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:96b38b8779941611c5a3@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:LLY P2 readout (est.): RENEW-Smk-1
DESCRIPTION:A Study of Brenipatide in Adults Who Quit Smoking Cigarettes an
 d Want to Avoid Relapse\nNCT07223840 | PHASE2 | RECRUITING | sponsor: Eli 
 Lilly and Company\nPrimary completion date (ESTIMATED)\; top-line results 
 usually follow later.\nDate precision: month (shown on the first day)\nTic
 ker LLY (confidence 0.95)\nSource: https://clinicaltrials.gov/study/NCT072
 23840\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07223840
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c147175cd08f202d4adb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261009
DTEND;VALUE=DATE:20261010
SUMMARY:LLY APPROVAL: OLUMIANT
DESCRIPTION:Approved 2026-10-09: OLUMIANT (NDA207924 SUPPL10)\nConfidence: 
 confirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207924\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=207924
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:739b59e49142bb019ea0@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:LLY APPROVAL: OLUMIANT
DESCRIPTION:Approved 2026-09-25: OLUMIANT (NDA207924 SUPPL9)\nConfidence: c
 onfirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207924\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=207924
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:bb1487374e8fcfebfefb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260923
DTEND;VALUE=DATE:20260924
SUMMARY:LLY APPROVAL: ONSWIK
DESCRIPTION:Approved 2026-09-23: ONSWIK (BLA761408 ORIG1)\nConfidence: conf
 irmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761408\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761408
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:c581653c32031d307ca4@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260918
DTEND;VALUE=DATE:20260919
SUMMARY:LLY APPROVAL: INLURIYO
DESCRIPTION:Approved 2026-09-18: INLURIYO (NDA218881 SUPPL1)\nConfidence: c
 onfirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218881\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218881
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:d98d9ce817ba6626bfd7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260918
DTEND;VALUE=DATE:20260919
SUMMARY:LLY APPROVAL: VERZENIO
DESCRIPTION:Approved 2026-09-18: VERZENIO (NDA208716 SUPPL22)\nConfidence: 
 confirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=208716
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:4ec366c86390448eb853@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:LLY APPROVAL: MOUNJARO\; MOUNJARO (AUTOINJECTOR)\; MOUNJARO KWIKPEN
DESCRIPTION:Approved 2026-08-27: MOUNJARO\; MOUNJARO (AUTOINJECTOR)\; MOUNJ
 ARO KWIKPEN (NDA215866 SUPPL44)\nConfidence: confirmed\nTicker LLY (confid
 ence 0.95)\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.
 cfm?event=overview.process&ApplNo=215866\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215866
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:05829244ae34ed1cb49d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:LLY APPROVAL: MOUNJARO\; MOUNJARO (AUTOINJECTOR)\; MOUNJARO KWIKPEN
DESCRIPTION:Approved 2026-08-27: MOUNJARO\; MOUNJARO (AUTOINJECTOR)\; MOUNJ
 ARO KWIKPEN (NDA215866 SUPPL45)\nConfidence: confirmed\nTicker LLY (confid
 ence 0.95)\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.
 cfm?event=overview.process&ApplNo=215866\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215866
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:a2148587b73bddee06dc@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260826
DTEND;VALUE=DATE:20260827
SUMMARY:LLY APPROVAL: ZEPBOUND\; ZEPBOUND (AUTOINJECTOR)\; ZEPBOUND KWIKPEN
DESCRIPTION:Approved 2026-08-26: ZEPBOUND\; ZEPBOUND (AUTOINJECTOR)\; ZEPBO
 UND KWIKPEN (NDA217806 SUPPL41)\nConfidence: confirmed\nTicker LLY (confid
 ence 0.95)\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.
 cfm?event=overview.process&ApplNo=217806\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=217806
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:110dd4ba68988b18313c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260714
DTEND;VALUE=DATE:20260715
SUMMARY:LLY APPROVAL: RETEVMO
DESCRIPTION:Approved 2026-07-14: RETEVMO (NDA218160 SUPPL7)\nConfidence: co
 nfirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218160\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218160
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:814fe8c1f7af164c4fc0@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260714
DTEND;VALUE=DATE:20260715
SUMMARY:LLY APPROVAL: RETEVMO
DESCRIPTION:Approved 2026-07-14: RETEVMO (NDA213246 SUPPL17)\nConfidence: c
 onfirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213246\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=213246
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:2711c4146151465cb7ee@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260713
DTEND;VALUE=DATE:20260714
SUMMARY:LLY APPROVAL: VERZENIO
DESCRIPTION:Approved 2026-07-13: VERZENIO (NDA208716 SUPPL21)\nConfidence: 
 confirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=208716
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:84745ed7870becb91130@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260609
DTEND;VALUE=DATE:20260610
SUMMARY:LLY APPROVAL: EBGLYSS
DESCRIPTION:Approved 2026-06-09: EBGLYSS (BLA761306 SUPPL6)\nConfidence: co
 nfirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761306\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761306
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:08a2b797ca4a9a5e7f05@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260401
DTEND;VALUE=DATE:20260402
SUMMARY:LLY APPROVAL: FOUNDAYO
DESCRIPTION:Approved 2026-04-01: FOUNDAYO (NDA220934 ORIG1)\nConfidence: co
 nfirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220934\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220934
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:6dc35c166bc5c42853a4@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251219
DTEND;VALUE=DATE:20251220
SUMMARY:LLY APPROVAL: MOUNJARO\; MOUNJARO (AUTOINJECTOR)\; MOUNJARO KWIKPEN
DESCRIPTION:Approved 2025-12-19: MOUNJARO\; MOUNJARO (AUTOINJECTOR)\; MOUNJ
 ARO KWIKPEN (NDA215866 SUPPL39)\nConfidence: confirmed\nTicker LLY (confid
 ence 0.95)\nSource: https://www.accessdata.fda.gov/scripts/cder/daf/index.
 cfm?event=overview.process&ApplNo=215866\nScheduling/reference data from p
 ublic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215866
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:2b8c91163a9d527ad7eb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251120
DTEND;VALUE=DATE:20251121
SUMMARY:LLY APPROVAL: RETEVMO
DESCRIPTION:Approved 2025-11-20: RETEVMO (NDA218160 SUPPL6)\nConfidence: co
 nfirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218160\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218160
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:bc257c350dfc0d95db3b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251120
DTEND;VALUE=DATE:20251121
SUMMARY:LLY APPROVAL: RETEVMO
DESCRIPTION:Approved 2025-11-20: RETEVMO (NDA213246 SUPPL15)\nConfidence: c
 onfirmed\nTicker LLY (confidence 0.95)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213246\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=213246
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
